Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 8/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12021295 | 1.00 | SRC (0.48) | SRCUSP30MCL1ABCB1MEN1 | |
| SCHEMBL12021345 | 0.89 | USP30 (0.44) | SRCUSP30MCL1ABCB1 | |
| SCHEMBL1751337 | 0.89 | USP30 (0.44) | SRCUSP30MCL1ABCB1 | |
| SCHEMBL24739133 | 0.88 | P2RX3 (0.47) | SRCMCL1MEN1KMT2A | |
| SCHEMBL12021060 | 0.88 | USP30 (0.45) | SRCUSP30MCL1ABCB1 | |
| SCHEMBL12037518 | 0.88 | USP30 (0.45) | SRCUSP30MCL1ABCB1 | |
| SCHEMBL18618199 | 0.88 | TACR1 (0.41) | SRCMCL1 | |
| SCHEMBL18618195 | 0.88 | TACR1 (0.41) | SRCMCL1 | |
| SCHEMBL15678324 | 0.88 | MCL1 (0.48) | USP30MCL1ABCB1 | |
| SCHEMBL14457266 | 0.88 | MCL1 (0.48) | USP30MCL1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022253101-A1 | PYRIDAZINONE COMPOUND AS PARP7 INHIBITOR | 上海优理惠生医药有限公司 | 2022-12-08 | — | — | WO | disclosed |
| US-11358950-B2 | SMAC mimetics used as IAP inhibitors and use thereof | CHIA TAI TIANGQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
| EP-3936126-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-01-12 | — | — | EP | disclosed |
| US-20210371400-A1 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-02 | — | — | US | disclosed |
| US-9840464-B2 | IAP binding compounds | TetraLogic Birinapant UK Ltd. (GB) | 2017-12-12 | — | — | US | disclosed |
| US-9840464-B2 | IAP binding compounds | TetraLogic Birinapant UK Ltd. (GB) | 2017-12-12 | — | — | US | disclosed |
| EP-2534170-B1 | IAP BIR DOMAIN BINDING COMPOUNDS | PHARMASCIENCE INC (CA) | 2017-04-19 | — | — | EP | disclosed |
| US-20160289183-A1 | IAP Binding Compounds | TETRALOGIC PHARMACEUTICALS CORPORATION | 2016-10-06 | — | — | US | disclosed |
| US-20160289183-A1 | IAP Binding Compounds | TETRALOGIC PHARMACEUTICALS CORPORATION | 2016-10-06 | — | — | US | disclosed |
| US-20090048183-A1 | IAP BINDING COMPOUNDS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2009-02-19 | — | — | US | disclosed |
| US-7456209-B2 | IAP binding compounds | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456209-B2 | IAP binding compounds | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289183-A1 | IAP Binding Compounds | BIRC5, API5, BIRC2 | SRC 4127/4885USP30 803/4885MCL1 41/4885 |
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | SRC 2590/4885USP30 4522/4885MCL1 340/4885 |
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | BIRC5, XIAP, BIRC2 | SRC 2274/4885USP30 524/4885MCL1 133/4885 |
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | SRC 2660/4885USP30 4484/4885MCL1 441/4885 |
| US-20210371400-A1 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | BIRC7, BIRC5, BIRC2 | SRC 3365/4885USP30 666/4885MCL1 16/4885 |
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | SRC 1841/4885USP30 4692/4885MCL1 1983/4885 |
| US-11358950-B2 | SMAC mimetics used as IAP inhibitors and use thereof | BIRC7, BIRC5, BIRC2 | SRC 3365/4885USP30 666/4885MCL1 16/4885 |
| US-20090048183-A1 | IAP BINDING COMPOUNDS | BIRC5, BIRC2, API5 | SRC 4024/4885USP30 858/4885MCL1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.